Cover Image
Market Research Report
Product code 
1092264

U.S. Digital Therapeutics Market - Industry Outlook and Forecast 2022-2027

Published: | Arizton Advisory & Intelligence | 188 Pages | Delivery time: 1-2 business days

Price

Back to Top
U.S. Digital Therapeutics Market - Industry Outlook and Forecast 2022-2027
Published: June 20, 2022
Arizton Advisory & Intelligence
Content info: 188 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Digital Therapeutics market in the U.S. is expected to grow at a CAGR of 33.15% during 2022-2027

The following factors are likely to contribute to the growth of the U.S. digital therapeutics market:

  • Rise in Chronic Diseases and Need for Controlling Healthcare Costs
  • Increase in Adoption of Healthcare Applications & Smart Wearables
  • Rising Importance of A.I. in Digital Therapeutics
  • Growing demand for Virtual Reality in DTx

MARKET OVERVIEW

Healthcare and technology have merged and created a new category of digital health known as digital therapeutics. It is a subset of digital health and a form of digital medicine that can maximize patient care and healthcare outcomes through independent use or in conjunction with pharmaceuticals. Examples of digital therapeutics include- wearable devices, digital sensors, and artificial intelligence-powered devices.

Digital therapeutics plays a significant role in the treatment and disease management of various chronic and mental health conditions. It presents potential solutions for chronic disease management, ranging from congestive heart failure, type 2 diabetes, Alzheimer's disease, and cancer. Common and expensive chronic conditions include diabetes, obesity, hypertension, heart disease, Alzheimer's disease, depression, arthritis, anxiety, and sleep disorders.

Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. DTx products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. Regulatory bodies must validate them to support product claims about risk, efficacy, and intended use. It empowers patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high-quality, safe, and effective data-driven interventions.

Regulatory jurisdictions most frequently categorize digital therapeutics as a subset of software as a Medical Device (SaMD), a framework developed by the International Medical Device Regulators Forum (IMDRF). All DTx products qualify as SaMD, but not all SaMD products are approved as digital therapeutic. However, a dedicated FDA regulatory framework for SaMD products remains in flux. Some DTx must undergo randomized controlled trials under the premarket approval process to demonstrate safety and efficacy like traditional pharmaceuticals.

Entry of Several Start-ups and Rapid Surge in Funding & Investments for DTx Companies

The goal of digital therapeutics is to treat chronic conditions at scale, relieving some of the significant stressors on the medical system, such as physician shortages. With the rise in the prevalence of chronic diseases, there has been a growing awareness of digital therapeutics. Owing to the gradual adoption of DTx, several companies have emerged in digital therapeutics, working with extreme expertise and intent to satisfy therapeutic needs. Furthermore, digital therapeutics saw significant funding growth in 2021, with start-ups delivering medical interventions using evidence-based software for managing and treating a broad spectrum of diseases reporting surging investments. Investments in DTx were at a record in 2020 with $1,065 million with 64 deals. DTx start-ups are likely to increase at an incredible rate, and competition is fierce for the favor of providers, payors, and employers.

Digital therapeutic solutions have caught the eye of big pharmaceutical organizations that started to invest and form strategic alliances with digital therapeutic companies. The rising need to create value beyond drug discoveries, increasing pricing pressures, and the steady incline in chronic and complex diseases all around the globe have majorly contributed to these partnerships. For instance, in early 2021, Click Therapeutics and Otsuka Pharmaceuticals announced a new remote clinical trial conducted on Verily's Project Baseline platform. In addition to this, many DTx companies have attracted significant venture and private equity financing to compete with traditional biotech pharma & companies developing drugs for similar indications. For instance, Pear Therapeutics developing DTx for substance and opioid use disorder raised around $139 million.

Digital therapeutics and telehealth companies can contribute to solutions more effectively than ever by leveraging data available from wearables and other digital sources. These technologies can drive more profound insight, influencing patient behaviors to prevent and manage chronic conditions. With the pandemic significantly raising the adoption of telehealth and virtual care, telehealth companies are looking up to digital therapeutic platforms to enhance the value of their services. For example, Aetna's telehealth business unit, Healthagen, collaborated with Welldoc and LifeScan to assess the usage and potential health benefits of OneTouch Reveal Plus.

Artificial Intelligence & Virtual Reality assisted Digital Therapeutics.

Software applications are playing a significant role in providing digital therapeutic solutions. Mobile app-based digital therapeutic programs are being delivered at a low cost and massive scale, helping prevent disease progression and potentially saving insurers billions of dollars. Some digital therapeutics are entirely replacing medication with behavioral-based treatment, such as apps that use visualization exercises to help people with insomnia.

For the DTx industry specifically, where many new and innovative applications are launched frequently, A.I. plays a major role in driving personalization and engagement to help patients achieve better health. AI-enabled therapeutics offer diagnosis and personalized care by tailoring the treatment itself and anticipating needs and challenges based on the individual's behavior. Digital therapeutics coupled with artificial intelligence (A.I.) and machine learning (ML) allows more effective clinical observations and management at the population level for various health conditions. Furthermore, virtual reality in digital therapeutics is gaining significant attention. It focuses on mental health, such as studying the mental states based on brainwave patterns. It also targets the promotion of healthy lifestyles through innovative virtual coaching.

Impact of COVID-19 on Digital Therapeutics

After the COVID-19 pandemic broke out, the utilization of DTx applications in various fields boomed. DTx provides unique solutions to satisfy healthcare needs, reducing the danger of COVID-19 exposure during a hospital visit. The COVID-19 pandemic joined the other major drivers for the growth of DTx, such as enhanced focus on preventive healthcare, high incidence of chronic diseases, and affordable gadgets due to technological advancements. In the post COVID era, DTx became a dominant player in the digital health industry, and its scope is likely to rise.

Insights by application

In 2021, the treatment & disease management segment accounted for the largest share of more than 80%. This treatment & management market will increase its domination during the forecast period and is likely to grow at a faster growth. This segment includes managing and treating diseases like chronic care, mental health & neurological disorders by using DTx. Digital therapeutics are being increasingly adopted due to the growing concern of chronic diseases. It is intended to help patients change their behaviors, often through cognitive-behavioral therapy (CBT), to successfully implement care plans for their chronic health or mental health conditions.

  • Treatment & Disease Management: Vendors targeting the treatment and management of various diseases are Teladoc, Canary Health, Noom, Cognoa, Pear Therapeutics, CureApp, 2Morrow, Sharecare, and others
  • Preventive Care: This includes pre-diabetes, weight management, and others. Vendors involved in providing digital therapeutics in these areas are Omada Health, One drop, WellDoc, Lark Health, and others.

Insights by End-users

In 2021, healthcare providers accounted for the largest share of 29.11% in the digital therapeutics market in the U.S. Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions. It promises many advantages for physicians, care providers, patients, payers, employers, and other stakeholders. As primary end-users, patients are at the core of the DTx landscape. Most therapies are delivered via smartphones or tablets to patients, increasing access to care compared to traditional treatments.

Segmentation by Application

  • Treatment & Disease Management
    • Chronic Care
    • Mental Health & Neurological Disorders
    • Others
  • Preventive Care
    • Pre-Diabetes
    • Weight Management
    • Others

Segmentation by End-User

  • Healthcare Providers
  • Patients/Individuals
  • Payers
  • Employers
  • Others

COMPETITIVE SCENARIO

Vendors dominating the digital therapeutics market are developing strategies such as partnerships, collaborations, joint ventures, mergers, and acquisitions for their growth and establishment. Major companies made successful partnerships to advance the adoption of DTx. Noom and Eversana partnered up to cater to patients with chronic conditions and rare diseases and check patient adherence and engagement for long-drawn-out therapies. The consolidation in the digital therapeutics market continues with vendors indulging in strategic acquisitions and collaborations with pharmaceutical companies to enter the digital therapeutics space and extend their presence in the market. Some significant acquisitions also took place in the DTx market. These include Biofourmis acquiring Gaido Health, Virgin Pulse acquiring Blue Mesa, and Novartis acquiring the digital therapeutics firm, Amblyotech. Over the next five years, there will likely be an uptick in mergers and acquisitions and closures among DTx companies.

Key Vendors

  • 2Morrow
  • Akili Interactive Labs
  • Cognoa
  • Fitbit
  • Kaia Health
  • Lark Technologies
  • Teladoc Health
  • Omada Health
  • Pear Therapeutics
  • ResMed
  • Voluntis
  • WellDoc
  • Dario Health
  • Happify Health
  • One Drop
  • Virta Health

Other Prominent Vendors

  • Ayogo
  • BehaVR
  • Calibrate Health
  • Canary Health
  • Cara Care
  • CardioRenal
  • Cerebral
  • CogniFit
  • CureApp
  • Freespira
  • Ginger
  • Glooko
  • Kelvi
  • Mahana Therapeutics
  • Mantra Health
  • Meru Health
  • Monument
  • Neurotrack Technologies
  • NightWare
  • Noom
  • Sharecare
  • SWORD Health
  • Talkspace
  • Thirty Madison
  • TRIPP
  • Vida Health
  • Vivante Health
  • Workit Health

KEY QUESTIONS ANSWERED

  • 1. HOW BIG IS THE U.S. DIGITAL THERAPEUTICS MARKET?
  • 2. WHAT IS THE GROWTH RATE OF THE DIGITAL THERAPEUTICS MARKET IN THE UNITED STATES?
  • 3. WHAT ARE THE KEY COMPANIES IN THE DIGITAL THERAPEUTICS MARKET IN U.S.?
  • 4. WHAT ARE THE MAJOR DRIVERS IN THE US DIGITAL THERAPEUTICS MARKET?
  • 5. WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE US DIGITAL THERAPEUTICS MARKET?
Product Code: Sample_Digital Therapeutics Market in the US - Industry Outlook & Forecast 2022-2027_Arizton.pdf

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY APPLICATION
    • 4.3.2 MARKET SEGMENTATION BY END-USER

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW
    • 7.1.1 STEPS TO INTEGRATE DIGITAL THERAPEUTICS
    • 7.1.2 CORE PRINCIPLES FOR DIGITAL THERAPEUTIC PRODUCTS
    • 7.1.3 DIGITAL THERAPEUTIC PRODUCT CATEGORIES
    • 7.1.4 SOME MAJOR MILESTONES IN DTX HISTORY
  • 7.2 SOFTWARE AS A MEDICAL DEVICE (SAMD)
  • 7.3 REGULATORY SCENARIO
  • 7.4 REIMBURSEMENT SCENARIO
  • 7.5 MAJOR FDA APPROVED DIGITAL THERAPEUTICS
  • 7.6 IMPACT OF COVID-19 ON DIGITAL THERAPEUTICS

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 MARKET ENTRY OF NUMEROUS DTX START-UPS
  • 8.2 STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
  • 8.3 RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
  • 8.4 PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
  • 8.5 TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES

9 MARKET GROWTH ENABLERS

  • 9.1 RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
  • 9.2 INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
  • 9.3 ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
  • 9.4 RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
  • 9.5 GROWING DEMAND FOR VIRTUAL REALITY IN DTX

10 MARKET GROWTH RESTRAINTS

  • 10.1 GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
  • 10.2 ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
  • 10.3 CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
  • 11.2 MARKET SIZE & FORECAST
    • 11.2.1 INSIGHTS BY APPLICATION
    • 11.2.2 INSIGHTS BY TREATMENT & DISEASE MANAGEMENT
    • 11.2.3 INSIGHTS BY PREVENTIVE CARE
    • 11.2.4 INSIGHTS BY END-USERS
  • 11.3 FIVE FORCES ANALYSIS
    • 11.3.1 THREAT OF NEW ENTRANTS
    • 11.3.2 BARGAINING POWER OF SUPPLIERS
    • 11.3.3 BARGAINING POWER OF BUYERS
    • 11.3.4 THREAT OF SUBSTITUTES
    • 11.3.5 COMPETITIVE RIVALRY

12 APPLICATION

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW

13 TREATMENT & DISEASE MANAGEMENT

  • 13.1 MARKET OVERVIEW
  • 13.2 MARKET SIZE & FORECAST
  • 13.3 CHRONIC CARE
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
  • 13.4 MENTAL HEALTH & NEUROLOGICAL DISORDERS
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
  • 13.5 OTHERS
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST

14 PREVENTIVE CARE

  • 14.1 MARKET OVERVIEW
  • 14.2 MARKET SIZE & FORECAST
  • 14.3 PRE-DIABETES
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
  • 14.4 WEIGHT MANAGEMENT
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
  • 14.5 OTHERS
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST

15 END-USER

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 HEALTHCARE PROVIDERS
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
  • 15.4 PATIENTS/ INDIVIDUALS
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
  • 15.5 PAYERS
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
  • 15.6 EMPLOYERS
    • 15.6.1 MARKET OVERVIEW
    • 15.6.2 MARKET SIZE & FORECAST
  • 15.7 OTHERS
    • 15.7.1 MARKET OVERVIEW
    • 15.7.2 MARKET SIZE & FORECAST

16 COMPETITIVE LANDSCAPE

  • 16.1 COMPETITION OVERVIEW
  • 16.2 MARKET SHARE ANALYSIS

17 KEY COMPANY PROFILES

  • 17.1 2MORROW
    • 17.1.1 BUSINESS OVERVIEW
    • 17.1.2 PRODUCT OFFERINGS
    • 17.1.3 KEY STRATEGIES
    • 17.1.4 KEY STRENGTHS
    • 17.1.5 KEY OPPORTUNITIES
  • 17.2 AKILI INTERACTIVE LABS
    • 17.2.1 BUSINESS OVERVIEW
    • 17.2.2 PRODUCT OFFERINGS
    • 17.2.3 KEY STRATEGIES
    • 17.2.4 KEY STRENGTHS
    • 17.2.5 KEY OPPORTUNITIES
  • 17.3 COGNOA
    • 17.3.1 BUSINESS OVERVIEW
    • 17.3.2 PRODUCT OFFERINGS
    • 17.3.3 KEY STRATEGIES
    • 17.3.4 KEY STRENGTHS
    • 17.3.5 KEY OPPORTUNITIES
  • 17.4 FITBIT
    • 17.4.1 BUSINESS OVERVIEW
    • 17.4.2 PRODUCT OFFERINGS
    • 17.4.3 KEY STRATEGIES
    • 17.4.4 KEY STRENGTHS
    • 17.4.5 KEY OPPORTUNITIES
  • 17.5 KAIA HEALTH
    • 17.5.1 BUSINESS OVERVIEW
    • 17.5.2 PRODUCT OFFERINGS
    • 17.5.3 KEY STRATEGIES
    • 17.5.4 KEY STRENGTHS
    • 17.5.5 KEY OPPORTUNITIES
  • 17.6 LARK TECHNOLOGIES
    • 17.6.1 BUSINESS OVERVIEW
    • 17.6.2 PRODUCT OFFERINGS
    • 17.6.3 KEY STRATEGIES
    • 17.6.4 KEY STRENGTHS
    • 17.6.5 KEY OPPORTUNITIES
  • 17.7 TELADOC HEALTH
    • 17.7.1 BUSINESS OVERVIEW
    • 17.7.2 PRODUCT OFFERINGS
    • 17.7.3 KEY STRATEGIES
    • 17.7.4 KEY STRENGTHS
    • 17.7.5 KEY OPPORTUNITIES
  • 17.8 OMADA HEALTH
    • 17.8.1 BUSINESS OVERVIEW
    • 17.8.2 PRODUCT OFFERINGS
    • 17.8.3 KEY STRATEGIES
    • 17.8.4 KEY STRENGTHS
    • 17.8.5 KEY OPPORTUNITIES
  • 17.9 PEAR THERAPEUTICS
    • 17.9.1 BUSINESS OVERVIEW
    • 17.9.2 PRODUCT OFFERINGS
    • 17.9.3 KEY STRATEGIES
    • 17.9.4 KEY STRENGTHS
    • 17.9.5 KEY OPPORTUNITIES
  • 17.10 RESMED
    • 17.10.1 BUSINESS OVERVIEW
    • 17.10.2 PRODUCT OFFERINGS
    • 17.10.3 KEY STRATEGIES
    • 17.10.4 KEY STRENGTHS
    • 17.10.5 KEY OPPORTUNITIES
  • 17.11 VOLUNTIS
    • 17.11.1 BUSINESS OVERVIEW
    • 17.11.2 PRODUCT OFFERINGS
    • 17.11.3 KEY STRATEGIES
    • 17.11.4 KEY STRENGTHS
    • 17.11.5 KEY OPPORTUNITIES
  • 17.12 WELLDOC
    • 17.12.1 BUSINESS OVERVIEW
    • 17.12.2 PRODUCT OFFERINGS
    • 17.12.3 KEY STRATEGIES
    • 17.12.4 KEY STRENGTHS
    • 17.12.5 KEY OPPORTUNITIES
  • 17.13 DARIO HEALTH
    • 17.13.1 BUSINESS OVERVIEW
    • 17.13.2 PRODUCT OFFERINGS
    • 17.13.3 KEY STRATEGIES
    • 17.13.4 KEY STRENGTHS
    • 17.13.5 KEY OPPORTUNITIES
  • 17.14 HAPPIFY HEALTH
    • 17.14.1 BUSINESS OVERVIEW
    • 17.14.2 PRODUCT OFFERINGS
    • 17.14.3 KEY STRATEGIES
    • 17.14.4 KEY STRENGTHS
    • 17.14.5 KEY OPPORTUNITIES
  • 17.15 ONE DROP
    • 17.15.1 BUSINESS OVERVIEW
    • 17.15.2 PRODUCT OFFERINGS
    • 17.15.3 KEY STRATEGIES
    • 17.15.4 KEY STRENGTHS
    • 17.15.5 KEY OPPORTUNITIES
  • 17.16 VIRTA HEALTH
    • 17.16.1 BUSINESS OVERVIEW
    • 17.16.2 PRODUCT OFFERINGS
    • 17.16.3 KEY STRATEGIES
    • 17.16.4 KEY STRENGTHS
    • 17.16.5 KEY OPPORTUNITIES

18 OTHER PROMINENT VENDORS

  • 18.1 AYOGO
    • 18.1.1 BUSINESS OVERVIEW
    • 18.1.2 PRODUCT OFFERINGS
  • 18.2 BEHAVR
    • 18.2.1 BUSINESS OVERVIEW
    • 18.2.2 PRODUCT OFFERINGS
  • 18.3 CALIBRATE HEALTH
    • 18.3.1 BUSINESS OVERVIEW
    • 18.3.2 PRODUCT OFFERINGS
  • 18.4 CANARY HEALTH
    • 18.4.1 BUSINESS OVERVIEW
    • 18.4.2 PRODUCT OFFERINGS
  • 18.5 CARA CARE
    • 18.5.1 BUSINESS OVERVIEW
    • 18.5.2 PRODUCT OFFERINGS
  • 18.6 CARDIORENAL
    • 18.6.1 BUSINESS OVERVIEW
    • 18.6.2 PRODUCT OFFERINGS
  • 18.7 CEREBRAL
    • 18.7.1 BUSINESS OVERVIEW
    • 18.7.2 PRODUCT OFFERINGS
  • 18.8 COGNIFIT
    • 18.8.1 BUSINESS OVERVIEW
    • 18.8.2 PRODUCT OFFERINGS
  • 18.9 CUREAPP
    • 18.9.1 BUSINESS OVERVIEW
    • 18.9.2 PRODUCT OFFERINGS
  • 18.10 FREESPIRA
    • 18.10.1 BUSINESS OVERVIEW
    • 18.10.2 PRODUCT OFFERINGS
  • 18.11 GINGER
    • 18.11.1 BUSINESS OVERVIEW
    • 18.11.2 PRODUCT OFFERINGS
  • 18.12 GLOOKO
    • 18.12.1 BUSINESS OVERVIEW
    • 18.12.2 PRODUCT OFFERINGS
  • 18.13 KELVI
    • 18.13.1 BUSINESS OVERVIEW
    • 18.13.2 PRODUCT OFFERINGS
  • 18.14 MAHANA THERAPEUTICS
    • 18.14.1 BUSINESS OVERVIEW
    • 18.14.2 PRODUCT OFFERINGS
  • 18.15 MANTRA HEALTH
    • 18.15.1 BUSINESS OVERVIEW
    • 18.15.2 PRODUCT OFFERINGS
  • 18.16 MERU HEALTH
    • 18.16.1 BUSINESS OVERVIEW
    • 18.16.2 PRODUCT OFFERINGS
  • 18.17 METAME HEALTH
    • 18.17.1 BUSINESS OVERVIEW
    • 18.17.2 PRODUCT OFFERINGS
  • 18.18 MONUMENT
    • 18.18.1 BUSINESS OVERVIEW
    • 18.18.2 PRODUCT OFFERINGS
  • 18.19 NEUROTRACK TECHNOLOGIES
    • 18.19.1 BUSINESS OVERVIEW
    • 18.19.2 PRODUCT OFFERINGS
  • 18.20 NIGHTWARE
    • 18.20.1 BUSINESS OVERVIEW
    • 18.20.2 PRODUCT OFFERINGS
  • 18.21 NOOM
    • 18.21.1 BUSINESS OVERVIEW
    • 18.21.2 PRODUCT OFFERINGS
  • 18.22 SHARECARE
    • 18.22.1 BUSINESS OVERVIEW
    • 18.22.2 PRODUCT OFFERINGS
  • 18.23 SWORD HEALTH
    • 18.23.1 BUSINESS OVERVIEW
    • 18.23.2 PRODUCT OFFERINGS
  • 18.24 TALKSPACE
    • 18.24.1 BUSINESS OVERVIEW
    • 18.24.2 PRODUCT OFFERINGS
  • 18.25 THIRTY MADISON
    • 18.25.1 BUSINESS OVERVIEW
    • 18.25.2 PRODUCT OFFERINGS
  • 18.26 TRIPP
    • 18.26.1 BUSINESS OVERVIEW
    • 18.26.2 PRODUCT OFFERINGS
  • 18.27 VIDA HEALTH
    • 18.27.1 BUSINESS OVERVIEW
    • 18.27.2 PRODUCT OFFERINGS
  • 18.28 VIVANTE HEALTH
    • 18.28.1 BUSINESS OVERVIEW
    • 18.28.2 PRODUCT OFFERINGS
  • 18.29 WORKIT HEALTH
    • 18.29.1 BUSINESS OVERVIEW
    • 18.29.2 PRODUCT OFFERINGS

19 REPORT SUMMARY

  • 19.1 KEY TAKEAWAYS
  • 19.2 STRATEGIC RECOMMENDATIONS

20 QUANTITATIVE SUMMARY

  • 20.1 MARKET BY APPLICATION
  • 20.2 MARKET BY TREATMENT & DISEASE MANAGEMENT
  • 20.3 MARKET BY PREVENTIVE CARE
  • 20.4 MARKET BY END-USER

21 APPENDIX

  • 21.1 ABBREVIATIONS

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF THE US DIGITAL THERAPEUTICS MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 PATH TO LAUNCHING DIGITAL THERAPEUTICS
  • EXHIBIT 4 PRODUCT CATEGORIES OF DIGITAL THERAPEUTICS
  • EXHIBIT 5 WORKFLOW OF A SOFTWARE AS A MEDICAL DEVICE (SAMD)
  • EXHIBIT 6 US FDA REGULATORY FRAMEWORK FOR DIGITAL THERAPEUTICS
  • EXHIBIT 7 IMPACT OF MARKET ENTRY OF NUMEROUS DTX START-UPS
  • EXHIBIT 8 MAJOR DIGITAL THERAPEUTIC START-UP COMPANIES IN US
  • EXHIBIT 9 IMPACT OF STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
  • EXHIBIT 10 DIGITAL THERAPEUTICS & PHARMA DEALS BY THERAPEUTIC AREA
  • EXHIBIT 11 IMPACT OF RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
  • EXHIBIT 12 DIGITAL HEALTH FUNDING IN US 2010-2020 ($ BILLION)
  • EXHIBIT 13 NUMBER OF DEALS IN DIGITAL HEALTH 2011-2021
  • EXHIBIT 14 IMPACT OF PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
  • EXHIBIT 15 LIST OF DIGITAL THERAPEUTICS PIPELINE BY STAGE OF DEVELOPMENT FOR SELECT VENDORS
  • EXHIBIT 16 COMPARISON OF INTERVENTIONAL DIGITAL THERAPEUTICS CLINICAL TRIALS BY INDUSTRY & ACADEMIC INSTITUTES 2014-2019
  • EXHIBIT 17 IMPACT OF TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES
  • EXHIBIT 18 IMPACT OF RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
  • EXHIBIT 19 IMPACT OF INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
  • EXHIBIT 20 IMPACT OF ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
  • EXHIBIT 21 IMPACT OF RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
  • EXHIBIT 22 IMPACT OF GROWING DEMAND FOR VIRTUAL REALITY IN DTX
  • EXHIBIT 23 IMPACT OF GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
  • EXHIBIT 24 IMPACT OF ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
  • EXHIBIT 25 IMPACT OF CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES
  • EXHIBIT 26 US DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 27 US DIGITAL THERAPEUTICS MARKET BY APPLICATION
  • EXHIBIT 28 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
  • EXHIBIT 29 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE
  • EXHIBIT 30 US DIGITAL THERAPEUTICS MARKET BY END-USER
  • EXHIBIT 31 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 32 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
  • EXHIBIT 33 ANNUAL INCREMENT COST PER PERSON IN US FOR VARIOUS CONDITIONS
  • EXHIBIT 34 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: INCREMENTAL GROWTH
  • EXHIBIT 35 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: ABSOLUTE GROWTH
  • EXHIBIT 36 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
  • EXHIBIT 37 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 38 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR TREATMENT & DISEASE MANAGEMENT
  • EXHIBIT 39 US TREATMENT & DISEASE MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 40 US DIGITAL THERAPEUTICS MARKET BY CHRONIC CARE: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 41 US CHRONIC CARE DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 42 US DIGITAL THERAPEUTICS MARKET BY MENTAL HEALTH & NEUROLOGICAL DISORDERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 43 US MENTAL HEALTH & NEUROLOGICAL DISORDER DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 44 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 45 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
  • EXHIBIT 46 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET
  • EXHIBIT 47 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR PREVENTIVE CARE
  • EXHIBIT 48 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 49 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 50 US DIGITAL THERAPEUTICS MARKET BY PRE-DIABETES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 51 US PRE-DIABETES DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 52 US DIGITAL THERAPEUTICS MARKET BY WEIGHT MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 53 US WEIGHT MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 54 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 55 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
  • EXHIBIT 56 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 57 US DIGITAL THERAPEUTICS MARKET BY END-USER
  • EXHIBIT 58 BENEFITS OF DIGITAL THERAPEUTICS TO KEY STAKEHOLDERS
  • EXHIBIT 59 US DIGITAL THERAPEUTICS MARKET BY END-USER: INCREMENTAL GROWTH
  • EXHIBIT 60 US DIGITAL THERAPEUTICS MARKET BY END-USER: ABSOLUTE GROWTH
  • EXHIBIT 61 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 62 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS 2021-2027 ($ MILLION)
  • EXHIBIT 63 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 64 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS 2021-2027 ($ MILLION)
  • EXHIBIT 65 US DIGITAL THERAPEUTICS MARKET BY PAYERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 66 US DIGITAL THERAPEUTICS MARKET BY PAYERS 2021-2027 ($ MILLION)
  • EXHIBIT 67 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 68 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS 2021-2027 ($ MILLION)
  • EXHIBIT 69 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 70 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
  • EXHIBIT 71 GROWTH STRATEGIES BY TOP DIGITAL THERAPEUTIC COMPANIES
  • EXHIBIT 72 PURE AND DIVERSIFIED PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET
  • EXHIBIT 73 US DIGITAL THERAPEUTICS MARKET: MAJOR VENDOR'S STRENGTH & CAPABILITY ANALYSIS
  • EXHIBIT 74 POSITION OF MAJOR PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 US FDA APPROVED DIGITAL THERAPEUTICS (2010-2021)
  • TABLE 4 2MORROW: MAJOR PRODUCT OFFERINGS
  • TABLE 5 AKILI INTERACTIVE LABS: MAJOR PRODUCT OFFERINGS
  • TABLE 6 COGNOA: MAJOR PRODUCT OFFERINGS
  • TABLE 7 FITBIT: MAJOR PRODUCT OFFERINGS
  • TABLE 8 KAIA HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 9 LARK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
  • TABLE 10 TELADOC HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 11 OMADA HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 12 PEAR THERAPEUTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 13 RESMED: MAJOR PRODUCT OFFERINGS
  • TABLE 14 VOLUNTIS: MAJOR PRODUCT OFFERINGS
  • TABLE 15 WELLDOC: MAJOR PRODUCT OFFERINGS
  • TABLE 16 DARIO HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 17 HAPPIFY HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 18 ONE DROP: MAJOR PRODUCT OFFERINGS
  • TABLE 19 VIRTA HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 20 AYOGO: MAJOR PRODUCT OFFERINGS
  • TABLE 21 BEHAVR: MAJOR PRODUCT OFFERINGS
  • TABLE 22 CALIBRATE HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 23 CANARY HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 24 CARA CARE: MAJOR PRODUCT OFFERINGS
  • TABLE 25 CARDIORENAL: MAJOR PRODUCT OFFERINGS
  • TABLE 26 CEREBRAL: MAJOR PRODUCT OFFERINGS
  • TABLE 27 COGNIFIT: MAJOR PRODUCT OFFERINGS
  • TABLE 28 CUREAPP: MAJOR PRODUCT OFFERINGS
  • TABLE 29 FREESPIRA: MAJOR PRODUCT OFFERINGS
  • TABLE 30 GINGER: MAJOR PRODUCT OFFERINGS
  • TABLE 31 GLOOKO: MAJOR PRODUCT OFFERINGS
  • TABLE 32 KELVI: MAJOR PRODUCT OFFERINGS
  • TABLE 33 MAHANA THERAPEUTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 34 MANTRA HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 35 MERU HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 36 METAME HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 37 MONUMENT: MAJOR PRODUCT OFFERINGS
  • TABLE 38 NEUROTRACK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
  • TABLE 39 NIGHTWARE: MAJOR PRODUCT OFFERINGS
  • TABLE 40 NOOM: MAJOR PRODUCT OFFERINGS
  • TABLE 41 SHARECARE: MAJOR PRODUCT OFFERINGS
  • TABLE 42 SWORD HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 43 TALKSPACE: MAJOR PRODUCT OFFERINGS
  • TABLE 44 THIRTY MADISON: MAJOR PRODUCT OFFERINGS
  • TABLE 45 TRIPP: MAJOR PRODUCT OFFERINGS
  • TABLE 46 VIDA HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 47 VIVANTE HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 48 WORKIT HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 49 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021-2027 ($ MILLION)
  • TABLE 50 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 51 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021-2027 ($ MILLION)
  • TABLE 52 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021-2027 (%)
  • TABLE 53 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021-2027 ($ MILLION)
  • TABLE 54 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021-2027 (%)
  • TABLE 55 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 56 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021-2027 (%)